News

Kmart learns of pharmacy breach in Sebring, Fla., taking incident ‘very seriously’

BY Antoinette Alexander

HOFFMAN ESTATES, Ill. — Kmart has announced that its Kmart Pharmacy, located at 901 US 27 North, Sebring, Fla., was the subject of a data incident on or around May 27, 2012.
 


The incident was recently discovered on July 10, when an acquaintance of a now former employee returned a printed report containing prescription information that was inappropriately disclosed. The report contained customers’ names and addresses; the prescriber’s name and address; and prescription name, number, quantity and drug NDC number. Kmart stressed that the report did not contain any personal information related to customers’ driver’s license, insurance carriers, social security numbers, bank accounts, debit or credit cards or other financial information. Kmart added that it is not aware of any misuse of customer information as a result of the incident.
 


Kmart stated that it is committed to protecting the privacy of its customers and is taking this incident “very seriously.” Immediately upon learning of the incident, Kmart conducted a thorough investigation. On Wednesday, the pharmacy notified all affected customers.  

To help prevent an incident like this from happening in the future, the pharmacy also reviewed and updated all related policies and procedures, as needed, and conducted additional staff training.
 


Kmart is urging any customers seeking additional information regarding the incident to call (866) 871-4680 for further information.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

C2B Solutions helps healthcare companies more effectively influence patient behavior

BY Michael Johnsen

CINCINNATI – The Ohio-based start-up C2B Solutions is available to provide key healthcare consumer insights and strategy to help healthcare companies more effectively influence patient behavior, the company announced last week. 
 
Led by a veteran team of healthcare marketing experts, C2B Solutions uses consumer insights to help businesses improve marketing and patient education, connecting consumers to health care products, services and organizations.
 
At the core of its products and services is a proprietary segmentation model (patent pending), which classifies consumers according to their motivations regarding health and wellness, with more than 91% predictability, C2B Solutions noted. By having consumers answer a simple set of questions, a healthcare organization can tailor its patient interaction, education and advertising to a consumer’s preferences, increasing the likelihood of success.
 
“This level of consumer understanding is especially important in today’s changing health care environment, which is undergoing a dramatic shift in the way companies market their products and services,” said C2B Solutions VP and chief marketing officer Brent Walker. “In an environment under the Affordable Care Act where millions of consumers shop for their own coverage, and reimbursement is tied to patient outcomes, healthcare providers need to make sure they understand consumer motivations and how to influence their behavior,” Walker said. “For example, the compensation of many hospitals, Accountable Care Organizations, and health insurance companies is linked to meeting performance requirements against patient satisfaction and quality of care.”
 
A former marketing executive at Procter & Gamble, Walker said C2B Solutions’ insights and services translate across the healthcare industry, including health insurance companies, hospitals, pharmaceuticals and over-the-counter medicine manufacturers, retail pharmacy and employers. 
 
C2B Solutions provides the healthcare industry access to:
 
  • Its psychographic segmentation model for highly targeted and effective consumer engagement;
  • A robust research database with more than 15 million data points on health care consumer attitudes, motivations and behaviors; andPublications and presentations of its market research on health care consumers, including patients with specific health conditions. For example, the C2B Consumer Diagnostic is a comprehensive, 625-page reference manual on the U.S. health care consumer based on C2B Solutions’ market research.
Former Department of Health and Human Services Secretary Tommy Thompson believes that C2B Solutions can help link the best of both worlds — consumer desires and healthcare resources. From his foreword to the C2B Consumer Diagnostic, “Health care organizations must evolve in this new era by deeply understanding consumer attitudes and behaviors to anticipate what excellence in health care means to them,” Thompson wrote. “Patient care supported by consumer insights will help deliver the standards we expect from the American health care system of tomorrow.”
 
Not only does C2B Solutions’ proprietary research help companies better understand consumer behavior, it ultimately saves them money and time, Walker said. “We are seeing insurance plans scrambling to attract members on the health insurance exchanges with standardized offerings. We understand how to help them rise above the clutter and help the industry remain nimble and responsive to these changes.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Mylan acquires rights to Apsen’s Arixtra injection

BY Ryan Chavis

PITTSBURGH — Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. The drug is used to prevent deep vein thrombosis. Mylan is currently selling the drug in the United States through an arrangement with Aspen. Apotex is selling generic Arixtra, which will be transitioning to Mylan by the end of the year, the company stated. 
 
"The addition of Arixtra is an attractive opportunity to broaden the range of therapeutic categories we market in the United States, in both the hospital and retail settings, and bolster our growing portfolio of complex injectables to better meet our customers' needs," said Heather Bresch, Mylan CEO. 
 
Mylan will pay Apsen $225 million once the transaction is complete, with an additional $75 million that will be held in escrow and released when certain conditions are met. Aspen will supply Arixtra and its generic equivalent to Mylan. 
 
Arixtra and the authorized generic had sales in the United States of $18.8 million and $95.3 million, respectively, for the 12 months ending June 30, 2014, according to IMS Health data. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?